MedTrace Logo

Dry Eye Management With 3% Diquafosol Before and After Cataract Surgery

NCT04952987 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2021-07-07

No results posted yet for this study

Summary

The objective of this study is to evaluate the efficacy of Diquafosol 3% in the management of dry eyes before and after cataract surgery. Patients with pre-existing dry eyes and planned for cataract surgery will be started on Diquafosol eyedrops prior to surgery and treatment will be continued after cataract surgery. Eligible patients will undergo evaluation of dry eye at baseline and subsequently started on treatment with Diquafosol for the duration of 4 weeks before surgery. Further evaluations will be conducted on the day of surgery and at designated time points during and up to 12 weeks after surgery.

Conditions

  • Dry Eye

Interventions

DRUG

Diquafosol

Diquafosol (Diquas) is a P2Y2 receptor agonist which improves mucin and tear secretion

Sponsors & Collaborators

  • Santen Oy

    collaborator INDUSTRY

  • Mun Wai Lee

    lead OTHER

Principal Investigators

  • Mun Wai Lee, MD · LEC Eye Centre

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-01
Primary Completion
2021-12-30
Completion
2021-12-30

Countries

  • Malaysia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04952987 on ClinicalTrials.gov